Xhance ™ (fluticasone propionate) for the Treatment of Nasal Polyps
Xhance ™ (fluticasone propionate / previously known as OPN-375), a synthetic trifluorinated corticosteroid, is indicated for the treatment of nasal polyps in patients aged 18 years or older.
Intersect ENT, based in Menlo Park, California, is releasing in the U.S. its SINUVA sinus implant for treating nasal polyp disease in adults that underwent previous surgical sinus procedures. The device elutes mometasone furoate, a corticosteroi...
Follow me on Twitter @RobShmerling Let us sing the praises of good medical screening tests. These are the tests that can detect medical problems before they become untreatable and before they cause complications or even death. Even better are those screening tests that detect “predisease” — abnormalities that aren’t dangerous on their own but can lead to problems later. According to the US Preventive Services Task Force, relatively few screening tests are considered good enough to routinely recommend for adults, including mammography for breast cancer (women) Pap smear for cervical cancer (women) b...
We report the effect of EDS-FLU on QoL as measured by the Rhinosinusitis Disability Index (RSDI).
Abstract BACKGROUND: Despite adding Omalizumab to conventional therapy, several severe asthmatics still show poor disease control. We investigated the factors that may affect a reduced Omalizumab response in a large population of severe asthmatics. METHODS: 340 patients were retrospectively evaluated. FEV1%, FVC%, Asthma Control Test (ACT), fractional exhaled nitric oxide (FENO), possible step-downs/step-ups of concomitant therapies, exacerbations, disease control levels, ICS doses and SABA use, observed at the end of treatment, were considered as a response to Omalizumab. RESULTS: Age was an independent...
Oral corticosteroids are commonly used in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).1 However, the efficacy of oral-corticosteroid therapy varies between different patients with CRSwNP. IL-25 –mediated TH2-biased response is reported to be associated with corticosteroid sensitivity in airway inflammatory response,2 while their value for predicting oral-corticosteroid response to CRSwNP has not been completely evaluated.
ConclusionSignificant improvements over a range of subjective and objective endpoints, including a reduction in the need for sinus surgery by 61%, suggest that MF sinus implants may play an important role in management of recurrent NP.
Conclusion: In CRSwNP pts with asthma, DPL significantly improved all asthma-related items. Improvement correlated with reduced nasal polyp burden.
ConclusionsThese results suggest that the addition of montelukast to INCS should not be recommended in the treatment of postoperative CRSwNP patients. Level of Evidence1b Laryngoscope, 2017
ConclusionsAn international effort in the implementation of SUA patients registries could help to better understand the clinical features and to manage severe asthma, representing a non negligible socio‐economic burden for health services.This article is protected by copyright. All rights reserved.